Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus telitacicept vs rituximab in systemic lupus erythematosus
ChiCTR2500103738Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in systemic lupus erythematosus (SLE) comparing Combination (Arm A): rituximab plus telitacicept with Control (Arm B): rituximab (2 arms). Primary endpoint: BAFF level at week 26. Started Jun 2025; status: recruiting.
02
Drugs
rituximabtelitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500103738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103738.